Is Lynparza a chemotherapy drug or a targeted drug?

Olaparib is a targeted drug rather than a traditional chemotherapy drug. As a PARP (polyADP-ribose polymerase) inhibitor, the therapeutic mechanism of olaparib is significantly different from that of traditional chemotherapy drugs, mainly in its strong specificity and mechanism of action.

Olaparib, as a targeted drug, fights cancer cells by specifically inhibiting the activity of PARP enzymes. PARPenzyme plays an important role in the cell's DNA repair process, especially in repairing single-stranded DNA breaks. Cancer cells with mutated BRCA1 and BRCA2 genes are already defective in repairing double-stranded DNA breaks and are therefore particularly sensitive to PARP inhibitors. Lynparza blocks the PARP enzyme from repairing DNA damage in cancer cells and uses the principle of "synthetic lethality" to prevent cancer cells from repairing their damaged DNA, thereby selectively killing cancer cells while having less impact on normal cells.

Traditional chemotherapy drugs usually work by destroying the division process of cancer cells. They are often non-specific and affect the normal and rapidly dividing cells in the body, such as bone marrow, digestive tract epithelium, etc., thus causing many side effects. These side effects include nausea, vomiting, hair loss, and immunosuppression.

Relatively speaking, as a targeted drug, olaparib usually has mild side effects because its mechanism of action is designed based on specific biomarkers (such asBRCA mutations). Therefore, olaparib's side effects focus on specific defects in cancer cells, often including fatigue, nausea, anemia, etc., but do not affect normal cells as broadly as traditional chemotherapy drugs.

Olaparib is a targeted drug that works by selectively inhibiting the PARP enzyme to fight certain types of cancer, especially those with BRCAGenetically mutated cancer cells. Unlike traditional chemotherapy drugs, it does not rely on destroying the cell division process, but achieves anti-cancer effects through specific biological mechanisms, thereby reducing the impact and side effects on normal cells.